John Collins
Clayton Utz
Partner
Sydney
He is truly exceptional, offering pragmatic and prompt advice. He has secured major victories for his clients and is definitely one of the leading lights in Australian patent litigation.
– Chambers Asia Pacific
Overview
A leading litigator in the Intellectual Property & Technology space, with special expertise in international disputes in innovation-focused industries such as pharmaceuticals, biotech, medical devices, competition law, software development and telecommunications.
John is the National Practice Group Leader of the IP & Technology team.
Notable Work
- Novartis AG: acting in proceedings to enforce for blockbuster multiple sclerosis drugs Gilenya, Entresto, Stalevo, Aclasta, Zometa.
- Sandoz: acting in the long-running Lundbeck escitalopram (Lexapro) patent infringement litigation.
- Fresenius Kabi: acting in proceedings against Samsung Bioepis in connection with adalimumab
- Expert witness: acting as an expert witness on Australian patent law in US arbitral proceedings concerning Gilead’s HIV drug portfolio.
- Merck Sharp & Dohme: acting in competition litigation against BMS concerning blockbuster Keytruda.
- Apple: acted in connection with patent disputes against Chinese smartphone manufacturers
- AT&T: acted in contract dispute with local technology transfer.
- nbn, Optus and Telstra: acted in various patent and contract disputes concerning DPUs, compression and content technologies.
- GME: acted successfully in Federal Court registered design infringement proceedings.
Insights
High Court of Australia confirms limits on undertaking as to damages: Commonwealth loses appeal in clopidogrel PBS claim
12 Dec 2024 | Article
Read Insights
Tribunal grants Sandoz a section 223(9) patent licence, in long-running Lexapro litigation
15 Oct 2024 | Article
Read Insights
Media Release: Clayton Utz advises NSW Government on new company to operate world-leading viral vector manufacturing facility
4 Mar 2024 | Media Release
Read Insights
Sandoz secures a stay in the long-running escitalopram litigation
27 Jul 2023 | Article
Read Insights
Media Release: Clayton Utz takes out top awards at 2023 Managing IP Asia Pacific Awards
7 Jul 2023 | Media Release
Read Insights
Commonwealth loses appeal in Clopidogrel PBS damages undertaking case: important lessons for patentees and generics alike
27 Jun 2023 | Article
Read Insights
Legislation needed on patentability of computer-implemented inventions, after High Court divided in rare 3:3 judgment
18 Aug 2022 | Article
Read Insights
Media Release: Clayton Utz wins Intellectual Property Team of the Year at 2022 Lawyers Weekly Australian Law Awards
18 Aug 2022 | Media Release
Read Insights
Patent term extensions in Australia: when first isn't really first
8 Jul 2021 | Article
Read Insights
More sectors to be critical infrastructure, increased obligations, and wider government powers in draft Bill – so comment now
20 Nov 2020 | Article
Read Insights
Australian High Court adopts doctrine of exhaustion of patent rights: Refurbished printer cartridges do not infringe
13 Nov 2020 | Article
Read Insights
Commonwealth fails in its claim for compensation for delayed PBS listing of generic clopidogrel
29 Apr 2020 | Article
Read Insights
Media Release: Clayton Utz recognised as Copyright winner at the 2019 Managing IP Asia Awards
3 Apr 2019 | Media Release
Read Insights
Commonwealth claims on undertakings continue to be a risk for pharmaceutical patent owners
20 Dec 2018 | Article
Read Insights
Government releases recommendations on Part A - Telecommunications Consumer Safeguards Review
19 Nov 2018 | Article
Read Insights
Media Release: Clayton Utz's Government and Intellectual Property teams among winners at 2018 Lawyers Weekly Australian Law Awards
11 Sep 2018 | Media Release
Read Insights
New interception and access powers to encrypted communications and devices to affect carriers and device manufacturers
14 Aug 2018 | Article
Read Insights
Clayton Utz named Australia IP Transactions & Advisory Firm of the Year
3 Apr 2018 | Media Release
Read Insights
Federal Government responds to Productivity Commission Inquiry into Intellectual Property Arrangements
31 Aug 2017 | Article
Read Insights
Landmark damages decision sets new benchmark for patent infringement claims against generic companies
21 Mar 2017 | Article
Read Insights
Find other people to support you
Find People